Levothyroxine sodium- Xeris Pharmaceuticals
Alternative Names: XP-8121Latest Information Update: 04 Jun 2024
At a glance
- Originator Xeris Pharmaceuticals
- Class Aromatic amino acids; Small molecules; Thyroid hormones
- Mechanism of Action Thyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hypothyroidism
Most Recent Events
- 30 May 2024 Efficacy and safety data from a phase II trial in Hypothyroidism released by Xeris Pharmaceuticals
- 30 May 2024 Xeris Biopharma anticipates meeting with the US FDA to dicuss results of phase II trial later in 2024
- 09 May 2024 Xeris Pharmaceuticals completes phase-II clinical trials in Hypothyroidism in USA (SC) (NCT05823012)